Regeneron Pharmaceuticals, Inc. technical analysis
Technical analysis of Regeneron Pharmaceuticals, Inc. (stock) with the Montbon Method — Elliott Waves, moving averages and a 0–100 score.
What is Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a pharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of various diseases, including ophthalmological, allergic, inflammatory, cardiovascular, metabolic, neurological, infectious and rare conditions, as well as cancers and hematologic disorders. Its products include EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for familial hypercholesterolemia, and Kevzara for rheumatoid arthritis. The company collaborates with multiple partners to develop innovative therapies based on technologies such as RNAi, CRISPR/Cas9, and other therapeutic approaches.
Description generated automatically from public sources; it may be inaccurate or out of date.
Regeneron Pharmaceuticals, Inc.: latest session data
Closing values for September 4, 2026, computed on the last 12 months of prices.
Moving averages
21 sessions
816.04 $
+1.91%
50 sessions
737.35 $
+12.78%
200 sessions
730.46 $
+13.85%
Session levels
s2
825.10
Support
s1
834.29
Support
pivot
846.81
Pivot
r1
856.00
Resistance
r2
868.52
Resistance
How to read it
In the September 4, 2026 session Regeneron Pharmaceuticals, Inc. closed lower at 831.61 $, −1.41% versus the previous session.
The price sits above every moving average observed: +1.91% against the 21-session average, +12.78% against the 50 and +13.85% against the 200.
The 14-period RSI reads 61.9, in neutral territory.
MACD stands at 25.900 against a signal line at 29.027: the histogram is negative (−3.127).
ADX reads 44.8, indicating a marked directionality.
Levels computed on the latest session place supports at 834.29 and 825.10 $ and resistances at 856.00 and 868.52 $, around a pivot of 846.81.
The average daily range (ATR) is 20.018 $, or 2.41% of price.
Turnover was 234K shares, 38% of the 20-session average.
Over the last twelve months the price ranged between 590.83 and 859.34 $, and today stands −3.23% from the period high.
Measures computed on closing prices. They describe the past; they are not forecasts.
Score, Elliott Waves, moving averages and technical indicators — free, no card
If you're not registered we'll ask you to sign in (free), then open the REGN analysis.
How Montbon’s technical analysis works
Montbon analyses markets with Elliott Waves, multi-timeframe moving averages and a 0–100 score summarising the technical setup. It is an informational screening tool.
Elliott Waves
Wave counting to frame the price structure.
MTF moving averages
Moving averages across timeframes to read the trend.
0–100 score
A technical summary of the setup, updated daily.
FAQ about Regeneron Pharmaceuticals, Inc.
How is Regeneron Pharmaceuticals, Inc. analysed technically?
Technical analysis of Regeneron Pharmaceuticals, Inc. is based on price charts and indicators such as moving averages, RSI and MACD, to observe trend, momentum and volatility across different time horizons.
Which timeframes are used for Regeneron Pharmaceuticals, Inc.?
The daily and weekly charts are typically used for medium-to-long-term trends, while intraday charts (for example 1-hour or 15-minute) are used for short-term movements.
What are Elliott Waves applied to Regeneron Pharmaceuticals, Inc.?
Elliott Wave theory describes price moves as sequences of impulsive and corrective waves; applied to Regeneron Pharmaceuticals, Inc. it helps frame the technical structure of the historical chart and is not a forecast.
Other tickers to analyse
Disclaimer. For informational purposes only; not financial advice or a recommendation. Montbon Analytics is not an authorised financial intermediary.
Are you an issuer and want a correction or removal? Write to info@montbon.com.